Administered by:
Association of Semaglutide With #TobaccoUseDisorder in Patients With Type 2 Diabetes: https://www.acpjournals.org/doi/10.7326/M23-2718 “#Semaglutide was associated with lower risks for TUD-related health care measures in patients with comorbid #T2DM and #TUD compared with other antidiabetes medications including other #GLP1Ras, primarily within 30 days of prescription. These findings suggest the need for clinical trials to evaluate semaglutide’s potential for TUD treatment.”